New 3-substituted 4-(phenyl-N-alkyl)-piperazine and 4-(phenyl-N-alkyl)-piperidine compounds of Formula (1) wherein X is N, CH, or C, however X may only be C when the compound comprises a double bind at the dotted line; R.sub.1 is CF.sub.3, OSO.sub.2CF.sub.3, OSO.sub.2CH.sub.3, SOR.sub.7, SO.sub.2R.sub.7, COR.sub.7, CN, OR.sub.3, NO.sub.2, CONHR.sub.3, 3-thiophene, 2-thiophene, 3-furane, 2-furane, F, Cl, Br, or I; R.sub.2 is F, Cl, Br, I, CN, CF.sub.3, CH.sub.3, OCH.sub.3, OH, and NH.sub.2; R.sub.3 and R.sub.4 are independently H or a C.sub.1-C.sub.4 alkyl; R.sub.5 is a C.sub.1-C.sub.4 alkyl, an allyl, CH.sub.2SCH.sub.3, CH.sub.2CH.sub.2OCH.sub.3, CH.sub.2CH.sub.2CH.sub.2F, CH.sub.2CF.sub.3, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, or --(CH.sub.2)R.sub.6; R.sub.6 is a C.sub.3-C.sub.6 cycloalkyl, 2-tetrahydrofurane, or 3-tetra-hydrofurane; R.sub.7 is a C.sub.1-C.sub.3 alkyl, CF.sub.3, or N(R.sub.4).sub.2, and pharmaceutically acceptable salts thereof are disclosed. Also pharmaceutical compositions comprising the above compounds and methods wherein the above compounds are used for treatment of disorders in the central nervous system are disclosed. ##STR00001##